Persistence of statin treatment – the impact of analytic method when estimating drug survival

Q3 Medicine Norsk Epidemiologi Pub Date : 2021-01-01 DOI:10.5324/nje.v29i1-2.4052
Oteiza Francisco, Hanna Isabel Løyland, C. Bugge, I. Kristiansen, H. Støvring
{"title":"Persistence of statin treatment – the impact of analytic method when estimating drug survival","authors":"Oteiza Francisco, Hanna Isabel Løyland, C. Bugge, I. Kristiansen, H. Støvring","doi":"10.5324/nje.v29i1-2.4052","DOIUrl":null,"url":null,"abstract":"Background: There is ample evidence for several pharmaceutical treatments that adherence in terms oftreatment duration and dose is suboptimal. The actual drug intake cannot be observed directly in prescriptiondatabases, which only register drug redeemed and a limited number of patient characteristics. Consequently,the actual dose and duration of treatment must be inferred from observed redemptions. Persistence can thenbe expressed as treatment duration (also referred to as drug survival).Method: We used data from the Norwegian Prescription Database (NorPD) on redemptions of statins (ATCcodeC10AA) for the period 2010-2019 to explore three methods for determining prescription durations andin turn persistence (treatment duration): (i) The DDD-method using the number of DDD redeemed; (ii) Thedose-unit approach using the number of tablets redeemed; (iii) The reverse waiting time distribution method(WTD), which estimates prescription duration as the 90th percentile of the distribution within which patientsin ongoing treatment will have a new subsequent redemption. The three methods for estimating prescriptionduration were then used to estimate treatment duration using Kaplan Meier (KM) survival functions. For theDDD-method and the dose-unit approach we conducted sensitivity analyses assuming that one DDD or onetablet would last for 1.00, 1.25 or 2.00 days. We also tested the impact of grace periods in sensitivity analyses.Results: Treatment duration and drug survival varied substantially for the same patients depending on thechosen method, duration of a DDD or a tablet, and inclusion of grace periods. The 25th percentile of treatmentduration was 100 days for the DDD approach with one DDD per day, 100 days with the dose-unit approachwith one tablet per day and 453 days with the WTD approach.Conclusion: When estimating treatment duration from prescription databases one should be aware that thesemeasures of persistence are highly influenced by the chosen methodology. The choice of method should beinformed by the clinical context with a preference for use of methods based on a formal model.","PeriodicalId":35548,"journal":{"name":"Norsk Epidemiologi","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Norsk Epidemiologi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5324/nje.v29i1-2.4052","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 3

Abstract

Background: There is ample evidence for several pharmaceutical treatments that adherence in terms oftreatment duration and dose is suboptimal. The actual drug intake cannot be observed directly in prescriptiondatabases, which only register drug redeemed and a limited number of patient characteristics. Consequently,the actual dose and duration of treatment must be inferred from observed redemptions. Persistence can thenbe expressed as treatment duration (also referred to as drug survival).Method: We used data from the Norwegian Prescription Database (NorPD) on redemptions of statins (ATCcodeC10AA) for the period 2010-2019 to explore three methods for determining prescription durations andin turn persistence (treatment duration): (i) The DDD-method using the number of DDD redeemed; (ii) Thedose-unit approach using the number of tablets redeemed; (iii) The reverse waiting time distribution method(WTD), which estimates prescription duration as the 90th percentile of the distribution within which patientsin ongoing treatment will have a new subsequent redemption. The three methods for estimating prescriptionduration were then used to estimate treatment duration using Kaplan Meier (KM) survival functions. For theDDD-method and the dose-unit approach we conducted sensitivity analyses assuming that one DDD or onetablet would last for 1.00, 1.25 or 2.00 days. We also tested the impact of grace periods in sensitivity analyses.Results: Treatment duration and drug survival varied substantially for the same patients depending on thechosen method, duration of a DDD or a tablet, and inclusion of grace periods. The 25th percentile of treatmentduration was 100 days for the DDD approach with one DDD per day, 100 days with the dose-unit approachwith one tablet per day and 453 days with the WTD approach.Conclusion: When estimating treatment duration from prescription databases one should be aware that thesemeasures of persistence are highly influenced by the chosen methodology. The choice of method should beinformed by the clinical context with a preference for use of methods based on a formal model.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
他汀类药物治疗的持久性——分析方法在估计药物生存期时的影响
背景:有充分的证据表明,几种药物治疗在治疗时间和剂量方面的依从性不是最佳的。在处方数据库中不能直接观察到实际的药物摄入量,处方数据库只记录了使用的药物和有限数量的患者特征。因此,治疗的实际剂量和持续时间必须从观察到的赎回推断。持久性可以表示为治疗持续时间(也称为药物生存期)。方法:我们使用挪威处方数据库(NorPD) 2010-2019年期间他汀类药物(atcodec10aa)的赎回数据,探索确定处方持续时间和持续时间(治疗持续时间)的三种方法:(i) DDD法,使用DDD赎回数量;(ii)使用赎回片剂数量的剂量单位方法;(iii)反向等待时间分布法(WTD),将处方时间估计为分布的第90个百分位数,在该分布中,正在接受治疗的患者将有一个新的后续赎回。然后使用三种估计处方时间的方法,使用Kaplan Meier (KM)生存函数估计治疗时间。对于DDD法和剂量单位法,我们进行了敏感性分析,假设一个DDD或一片片剂的持续时间为1.00、1.25或2.00天。我们还在敏感性分析中测试了宽限期的影响。结果:根据所选择的方法、DDD或片剂的持续时间以及宽限期,同一患者的治疗时间和药物生存期存在很大差异。治疗时间的第25百分位数为DDD方法100天,每天1个DDD,剂量单位方法100天,每天1片,WTD方法453天。结论:当从处方数据库估计治疗持续时间时,人们应该意识到这些持久性的测量受到所选择的方法的高度影响。方法的选择应根据临床情况,优先使用基于正式模型的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Norsk Epidemiologi
Norsk Epidemiologi Medicine-Epidemiology
CiteScore
1.10
自引率
0.00%
发文量
25
审稿时长
12 weeks
期刊最新文献
The impact of longitudinal surveillance of individuals with CP in Norway; a 20-year quality registry and follow-up program perspective Nasjonalt register for gastrokirurgi (NORGAST): noen tanker etter ti år External validation of SAPS II score reported to the Norwegian Intensive Care and Pandemic Registry (NIPaR) MS-registeret: meget viktig for MS-pasientene og enda viktigere fremover Et lederperspektiv – nytten av medisinske kvalitetsregistre og hvordan vi bruker disse i forbedringsarbeid og praksisendring
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1